Clinical analysis of acetylcysteine effervescent tablets combined with tiotropium bromide inhalation in the treatment of patients with chronic obstructive pulmonary disease

doi:10.3877/cma.j.issn.1674-6902.2022.03.010

Abstract

Abstract:

Objective

To explore the application effects of acetylcysteine effervescent tablets combined with tiotropium bromide inhalation on patients with COPD (chronic obstructive pulmonary disease), so as to provide a method for the disease.

Methods

124 patients with COPD who were treated in the hospital were selected between April 2018 and October 2020 and were divided into 63 cases in observation group and 61 cases in control group. Control group was given tiotropium bromide inhalation and other conventional treatments, and observation group was combined with acetylcysteine effervescent tablets based on control group. The lung function indexes, blood gas indicators and levels of serum inflammatory factors were compared between the two groups before treatment and at 3 months of treatment. The airway limitation severity and dyspnea degree were compared between the two groups at 3 months of treatment.

Results

At 3 months of treatment, the FEV₁, FVC and FEV₁/FVC of the two groups were significantly enhanced compared with those before treatment, and the above indexes of observation group were significantly higher than those of control group (all P<0.05). The levels of serum IL-6, INF-γ and TNF-α were significantly reduced in the two groups compared to before treatment, and the levels of observation group were significantly lower than those of control group (all P<0.05). The PaO₂ of observation group at 3 months of treatment was significantly higher compared with that of control group while the PaCO₂ was significantly lower compared to control group (all P<0.05). The airflow limitation severity at 3 months of treatment was significantly milder in observation group than that in control group, and the dyspnea grading was significantly lower than that in control group (all P<0.05).

Conclusion

Acetylcysteine effervescent tablets combined with tiotropium bromide inhalation has a good application effect on patients with COPD.

Key words: Chronic obstructive pulmonary disease, Emphysema, Blood gas indicators, Lung function, Dyspnea

Yanyu Tang, Xia Tang, Lijuan Li. Clinical analysis of acetylcysteine effervescent tablets combined with tiotropium bromide inhalation in the treatment of patients with chronic obstructive pulmonary disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 335-338.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2022.03.010

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2022/V15/I03/335

Figures/Tables 4

References 20

1	Lareau SC, Fahy B, Meek P, et al. Chronic obstructive pulmonary disease (COPD)[J]. Am J Respir Crit Care Med, 2019, 199(1): 1-2.
2	陈　琰，钱　频，袁　琳. 慢性阻塞性肺疾病肺外合并症的治疗现状和研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 100-103.
3	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
4	郑劲平. 2019年版慢性阻塞性肺疾病全球倡议解读(药物治疗篇)[J]. 中华结核和呼吸杂志，2019, 42(2): 157-160.
5	李　凡，孙惠芬，段　静，等. 从GOLD指南的演变看慢性阻塞性肺疾病的防治[J]. 中国全科医学，2019, 22 (27): 3275-3280.
6	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南[J]. 中华内科杂志，2002, 5(9): 640-646.
7	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志，2013, 36(4): 255-264.
8	Lambert A, Iyer A, Regan EA, et al. Factors influencing decline in quality of life in smokers without airflow obstruction: The COPD Gene study[J]. Respir Med, 2020, 161: 105820.
9	陈华萍，甘志新，刘　刚，等. 慢性阻塞性肺疾病的合并症/并发症的发病率和病死率分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 417-421.
10	Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease [J]. N Engl J Med, 2017, 377(10): 923-935.
11	迟玉敏，邸庆国，李　敏，等. 乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床研究[J]. 中国临床药理学杂志，2018, 2(12): 124-128.
12	Rabe KF, Watz H. Chronic obstructive pulmonary disease[J]. Lancet, 2017, 389(10082): 1931-1940.
13	Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine[J]. Respir Res, 2019, 20(1): 104.
14	王波太. 噻托溴铵雾剂联合N-乙酰半胱氨酸泡腾片对慢性阻塞性肺疾病患者的临床疗效[J]. 实用临床医药杂志，2020, 24(20): 4.
15	Ansari SF, Memon M, Brohi N, et al. N-acetylcysteine in the management of acute exacerbation of chronic obstructive pulmonary disease[J]. Cureus, 2019, 11(11): e6073.
16	付　伟，辛丽云，陈乾华. 乙酰半胱氨酸溶液雾化吸入对COPD患者免疫功能及肺功能的影响[J]. 实用药物与临床，2019, 22(6): 597-600.
17	张　宇，张小辉，卢富明. 吸入乙酰半胱氨酸治疗COPD的疗效及对痰液粘稠度、气道阻力的影响[J]. 解放军预防医学杂志，2018, 36(9): 43-46.
18	龙　宇，董　敏，刘礼银，等. 乙酰半胱氨酸雾化吸入联合免疫球蛋白治疗老年肺炎疗效及对炎症因子的影响[J]. 中南医学科学杂志，2022, 50(2): 265-267.
19	严德斌，杨志明，孙炜佳. N-乙酰半胱氨酸对COPD患者血清炎性因子、免疫功能及肺功能的影响[J]. 海南医学院学报，2015, 21(12): 1627-1629, 1632.
20	李中祎，张　治，曹　路，等. N-乙酰半胱氨酸联合无创正压通气治疗COPD急性发作的临床分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 188-192.

组　别		例数	FEV₁(L)		FVC(L)		FEV₁/FVC(%)
组　别		例数	治疗前	治疗3个月	治疗前	治疗3个月	治疗前	治疗3个月
观察组		63	1.25±0.32	2.43±0.59^a	2.12±0.11	3.04±0.62^a	58.96±10.21	58.57±9.86^a
对照组		61	1.23±0.28	1.77±0.42^a	2.10±0.26	2.46±0.43^a	79.93±7.11	71.95±6.42^a
	t值		0.370	7.156	0.561	6.035	13.232	8.924
	P值		0.712	0.000	0.576	0.000	0.000	0.000

组　别		例数	FEV₁(L)		FVC(L)		FEV₁/FVC(%)
组　别		例数	治疗前	治疗3个月	治疗前	治疗3个月	治疗前	治疗3个月
观察组		63	1.25±0.32	2.43±0.59^a	2.12±0.11	3.04±0.62^a	58.96±10.21	58.57±9.86^a
对照组		61	1.23±0.28	1.77±0.42^a	2.10±0.26	2.46±0.43^a	79.93±7.11	71.95±6.42^a
	t值		0.370	7.156	0.561	6.035	13.232	8.924
	P值		0.712	0.000	0.576	0.000	0.000	0.000

组　别		例数	PaO₂		PaCO₂
组　别		例数	治疗前	治疗3个月	治疗前	治疗3个月
观察组		63	74.26±8.31	92.58±9.24^a	59.77±5.23	35.67±5.24^a
对照组		61	74.39±10.27	83.33±8.65^a	58.14±6.12	44.12±5.48^a
	t值		0.078	5.751	1.596	8.777
	P值		0.938	0.000	0.113	0.000

组　别		例数	PaO₂		PaCO₂
组　别		例数	治疗前	治疗3个月	治疗前	治疗3个月
观察组		63	74.26±8.31	92.58±9.24^a	59.77±5.23	35.67±5.24^a
对照组		61	74.39±10.27	83.33±8.65^a	58.14±6.12	44.12±5.48^a
	t值		0.078	5.751	1.596	8.777
	P值		0.938	0.000	0.113	0.000

组　别		例数	IL-6(pg/ml)		INF-γ(μg/ml)		TNF-α(ng/ml)
组　别		例数	治疗前	治疗3个月	治疗前	治疗3个月	治疗前	治疗3个月
观察组		63	17.20±2.08	9.65±1.24^a	14.62±2.63	8.33±1.32^a	2.35±0.52	1.12±0.41^a
对照组		61	17.13±3.10	10.58±2.02^a	14.69±2.87	9.82±1.60^a	2.39±0.63	1.68±0.53^a
	t值		0.148	3.101	0.142	5.664	0.386	6.593
	P值		0.883	0.002	0.888	0.000	0.700	0.000

Please choose a citation manager

Content to export